

Chiara Fabbri

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7312989/publications.pdf>

Version: 2024-02-01

152
papers

3,748
citations

182225

30
h-index

198040

52
g-index

189
all docs

189
docs citations

189
times ranked

4964
citing authors

#	ARTICLE	IF	CITATIONS
1	Depressive symptoms and neuroticism-related traits are the main factors associated with wellbeing independent of the history of lifetime depression in the UK Biobank. <i>Psychological Medicine</i> , 2023, 53, 3000-3008.	2.7	9
2	Depression with atypical neurovegetative symptoms shares genetic predisposition with immuno-metabolic traits and alcohol consumption. <i>Psychological Medicine</i> , 2022, 52, 726-736.	2.7	33
3	Identifying the Common Genetic Basis of Antidepressant Response. <i>Biological Psychiatry Global Open Science</i> , 2022, 2, 115-126.	1.0	31
4	Pregabalin augmentation of antidepressants in major depression - results from a European multicenter study. <i>Journal of Affective Disorders</i> , 2022, 296, 485-492.	2.0	3
5	A meta-analysis of polygenic risk scores for mood disorders, neuroticism, and schizophrenia in antidepressant response. <i>European Neuropsychopharmacology</i> , 2022, 55, 86-95.	0.3	19
6	Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 114, 110480.	2.5	3
7	Gambling Disorder in an Italian Population: Risk of Suicide Attempts and Associated Demographic-Clinical Factors using Electronic Health Records. <i>Journal of Gambling Studies</i> , 2022, 38, 1143-1156.	1.1	3
8	Social withdrawal as a trans-diagnostic predictor of short-term remission: a meta-analysis of five clinical cohorts. <i>International Clinical Psychopharmacology</i> , 2022, 37, 38-45.	0.9	9
9	Anxiety disorders and age-related changes in physiology. <i>British Journal of Psychiatry</i> , 2022, 221, 528-537.	1.7	10
10	Latent subtypes of manic and/or irritable episode symptoms in two population-based cohorts. <i>British Journal of Psychiatry</i> , 2022, 221, 722-731.	1.7	4
11	The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2022, 272, 715-727.	1.8	14
12	Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study. <i>European Neuropsychopharmacology</i> , 2022, 56, 100-111.	0.3	5
13	Latent subtypes of manic and/or irritable episode symptoms in two population-based cohorts "ERRATUM. <i>British Journal of Psychiatry</i> , 2022, , 1-2.	1.7	0
14	Anxiety disorders and age-related changes in physiology "ERRATUM. <i>British Journal of Psychiatry</i> , 2022, , 1-1.	1.7	1
15	Polygenic risk scores for neuropsychiatric, inflammatory, and cardio-metabolic traits highlight possible genetic overlap with suicide attempt and treatment-emergent suicidal ideation. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2022, 189, 74-85.	1.1	8
16	Genetics in psychiatry: Methods, clinical applications and future perspectives. , 2022, 1, .		3
17	COVID-19 hospitalization rates in individuals with substance or alcohol use disorders. <i>Psychiatry Research</i> , 2022, 311, 114521.	1.7	11
18	Imputed expression of schizophrenia-associated genes and cognitive measures in patients with schizophrenia. <i>Molecular Genetics & Genomic Medicine</i> , 2022, 10, e1942.	0.6	6

#	ARTICLE	IF	CITATIONS
19	The sociodemographic and clinical phenotype of European patients with major depressive disorder undergoing first-line antidepressant treatment with NaSSAs. <i>Journal of Affective Disorders</i> , 2022, 312, 225-234.	2.0	2
20	Pharmacogenetics in psychiatry: some key clinical considerations. <i>Minerva Psychiatry</i> , 2022, 63, .	0.3	0
21	The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?. <i>International Clinical Psychopharmacology</i> , 2022, 37, 263-275.	0.9	9
22	Clinical, demographic, and genetic risk factors of treatment-attributed suicidality in >10,000 Australian adults taking antidepressants. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2022, 189, 196-206.	1.1	2
23	Machine Learning Prediction of Comorbid Substance Use Disorders among People with Bipolar Disorder. <i>Journal of Clinical Medicine</i> , 2022, 11, 3935.	1.0	7
24	Drug repositioning for treatment-resistant depression: Hypotheses from a pharmacogenomic study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 104, 110050.	2.5	21
25	Cost-effectiveness of genetic and clinical predictors for choosing combined psychotherapy and pharmacotherapy in major depression. <i>Journal of Affective Disorders</i> , 2021, 279, 722-729.	2.0	7
26	Higher polygenic risk scores for schizophrenia may be suggestive of treatment non-response in major depressive disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 108, 110170.	2.5	36
27	Precision psychiatry in clinical practice. <i>International Journal of Psychiatry in Clinical Practice</i> , 2021, 25, 19-27.	1.2	25
28	Investigating an in silico approach for prioritizing antidepressant drug prescription based on drug-induced expression profiles and predicted gene expression. <i>Pharmacogenomics Journal</i> , 2021, 21, 85-93.	0.9	1
29	Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts. <i>Molecular Psychiatry</i> , 2021, 26, 3363-3373.	4.1	66
30	Genome-wide association study of suicidal behaviour severity in mood disorders. <i>World Journal of Biological Psychiatry</i> , 2021, 22, 1-19.	1.3	3
31	The Role of Relationship Status in Major Depressive Disorder - Results of the European Group for the Study of Resistant Depression. <i>Journal of Affective Disorders</i> , 2021, 286, 149-157.	2.0	4
32	Genetic underpinnings of sociability in the general population. <i>Neuropsychopharmacology</i> , 2021, 46, 1627-1634.	2.8	18
33	Oral Microbiome Dysbiosis Is Associated With Symptoms Severity and Local Immune/Inflammatory Response in COVID-19 Patients: A Cross-Sectional Study. <i>Frontiers in Microbiology</i> , 2021, 12, 687513.	1.5	88
34	Transcriptome-wide association study of treatment-resistant depression and depression subtypes for drug repurposing. <i>Neuropsychopharmacology</i> , 2021, 46, 1821-1829.	2.8	27
35	Pharmacogenetic-Guided Treatment of Depression: Real-World Clinical Applications, Challenges, and Perspectives. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 573-581.	2.3	11
36	Sex-related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression. <i>Depression and Anxiety</i> , 2021, 38, 896-906.	2.0	18

#	ARTICLE	IF	CITATIONS
37	Melancholic features in major depression – a European multicenter study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 110, 110285.	2.5	17
38	Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression. <i>Current Medicinal Chemistry</i> , 2021, 28, 4296-4320.	1.2	1
39	Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder - evidence from the European Group for the Study of Resistant Depression. <i>Journal of Psychiatric Research</i> , 2021, 141, 167-175.	1.5	14
40	The Choice of either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients with Major Depressive Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2021, , .	1.0	2
41	Vitamin D and the risk of treatment-resistant and atypical depression: A Mendelian randomization study. <i>Translational Psychiatry</i> , 2021, 11, 561.	2.4	9
42	An interview with Dr Chiara Fabbri: pharmacogenomics and drug repurposing for treatment-resistant depression. <i>Pharmacogenomics</i> , 2021, 22, 1107-1109.	0.6	0
43	Comparison of Mortality Rates between Italian and Foreign-born Patients with Alcohol Use Disorders. <i>Journal of Psychoactive Drugs</i> , 2021, , 1-11.	1.0	0
44	Genome-wide association study of antidepressant treatment resistance in a population-based cohort using health service prescription data and meta-analysis with GENDEP. <i>Pharmacogenomics Journal</i> , 2020, 20, 329-341.	0.9	45
45	Clinical application of antidepressant pharmacogenetics: Considerations for the design of future studies. <i>Neuroscience Letters</i> , 2020, 726, 133651.	1.0	14
46	Reduced plasma Fetuin-A is a promising biomarker of depression in the elderly. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 901-910.	1.8	8
47	Add-on benzodiazepine treatment in patients with major depressive disorder – results from a European cross-sectional multicenter study. <i>European Neuropsychopharmacology</i> , 2020, 41, 70-80.	0.3	14
48	Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment. <i>International Clinical Psychopharmacology</i> , 2020, 35, 233-242.	0.9	22
49	The Role of Genetics in Bipolar Disorder. <i>Current Topics in Behavioral Neurosciences</i> , 2020, 48, 41-60.	0.8	10
50	Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 571-577.	1.0	5
51	Defining the oral microbiome by whole-genome sequencing and resistome analysis: the complexity of the healthy picture. <i>BMC Microbiology</i> , 2020, 20, 120.	1.3	152
52	A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping. <i>Translational Psychiatry</i> , 2020, 10, 50.	2.4	33
53	Genetic variants associated with psychotic symptoms across psychiatric disorders. <i>Neuroscience Letters</i> , 2020, 720, 134754.	1.0	9
54	Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future. <i>Clinical Psychopharmacology and Neuroscience</i> , 2020, 18, 1-9.	0.9	23

#	ARTICLE	IF	CITATIONS
55	How to Utilize Clinical and Genetic Information for Personalized Treatment of Major Depressive Disorder: Step by Step Strategic Approach. <i>Clinical Psychopharmacology and Neuroscience</i> , 2020, 18, 484-492.	0.9	14
56	The search for personalized antidepressant treatments: what have we learned and where are we going. <i>Pharmacogenomics</i> , 2020, 21, 1095-1100.	0.6	2
57	Genetic basis of psychopathological dimensions shared between schizophrenia and bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 89, 23-29.	2.5	13
58	Results of the European Group for the Study of Resistant Depression (GSRD) – basis for further research and clinical practice. <i>World Journal of Biological Psychiatry</i> , 2019, 20, 427-448.	1.3	89
59	Is Pharmacogenetics Useful in Antidepressant Treatment?. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 916-918.	2.3	2
60	Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone. <i>European Neuropsychopharmacology</i> , 2019, 29, 971-985.	0.3	93
61	F105AN EXOME SEQUENCING STUDY IN TREATMENT-RESISTANT DEPRESSION. <i>European Neuropsychopharmacology</i> , 2019, 29, S1166-S1167.	0.3	0
62	META-ANALYSIS OF CYP2C19 ASSOCIATION WITH EFFICACY AND SIDE EFFECTS OF CITALOPRAM AND ESCITALOPRAM USING DATA FROM GENOME-WIDE ASSOCIATION STUDIES. <i>European Neuropsychopharmacology</i> , 2019, 29, S808.	0.3	0
63	Manifesto for an international digital mental health network. <i>Digital Psychiatry</i> , 2019, 2, 14-24.	2.1	14
64	PHARMACOGENETIC TESTING IN PSYCHIATRY: CRITICAL REVIEW OF EXISTING TESTING KITS AND CLINICAL TRIALS. <i>European Neuropsychopharmacology</i> , 2019, 29, S1064-S1065.	0.3	0
65	WHOLE EXOME SEQUENCING REVEALS RISK FACTORS IN TREATMENT RESISTANT DEPRESSION. <i>European Neuropsychopharmacology</i> , 2019, 29, S934-S935.	0.3	0
66	Uncovering neurodevelopmental features in bipolar affective disorder. <i>British Journal of Psychiatry</i> , 2019, 215, 383-385.	1.7	13
67	Single nucleotide polymorphisms (SNPs) implicated in determining predominant polarity in bipolar disorder. <i>European Neuropsychopharmacology</i> , 2019, 29, S378-S379.	0.3	0
68	Reduced CXCL1/GRO chemokine plasma levels are a possible biomarker of elderly depression. <i>Journal of Affective Disorders</i> , 2019, 249, 410-417.	2.0	12
69	Corrected QT Interval Prolongation in Psychopharmacological Treatment and Its Modulation by Genetic Variation. <i>Neuropsychobiology</i> , 2019, 77, 67-72.	0.9	13
70	Genome-wide association study of treatment-resistance in depression and meta-analysis of three independent samples. <i>British Journal of Psychiatry</i> , 2019, 214, 36-41.	1.7	44
71	Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 78-88.	2.2	92
72	The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives. <i>International Journal of Neuropsychopharmacology</i> , 2019, 22, 93-104.	1.0	32

#	ARTICLE	IF	CITATIONS
73	Pharmacogenetics and Depression: A Critical Perspective. <i>Psychiatry Investigation</i> , 2019, 16, 645-653.	0.7	17
74	Highlights on Pharmacogenetics and Pharmacogenomics in Depression. , 2018, , 3-16.		0
75	Pleiotropic genes in psychiatry: Calcium channels and the stress-related FKBP5 gene in antidepressant resistance. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 81, 203-210.	2.5	31
76	New insights into the pharmacogenomics of antidepressant response from the GENDEP and STAR*D studies: rare variant analysis and high-density imputation. <i>Pharmacogenomics Journal</i> , 2018, 18, 413-421.	0.9	40
77	The serotonin transporter and the activity regulated cytoskeleton-associated protein genes in antidepressant response and resistance: <i>5-HTTLPR</i> and other variants. <i>Human Psychopharmacology</i> , 2018, 33, e2682.	0.7	7
78	Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 86, 36-44.	2.5	39
79	Effect of cytochrome CYP2C19 metabolizing activity on antidepressant response and side effects: Meta-analysis of data from genome-wide association studies. <i>European Neuropsychopharmacology</i> , 2018, 28, 945-954.	0.3	64
80	Genes associated with anhedonia: a new analysis in a large clinical trial (GENDEP). <i>Translational Psychiatry</i> , 2018, 8, 150.	2.4	19
81	Genetic disposition to inflammation and response to antidepressants in major depressive disorder. <i>Journal of Psychiatric Research</i> , 2018, 105, 17-22.	1.5	18
82	Clinical efficacy of a chlorhexidine-based mouthrinse containing hyaluronic acid and an antidiscoloration system in patients undergoing flap surgery: A triple-blind, parallel-arm, randomized controlled trial. <i>International Journal of Dental Hygiene</i> , 2018, 16, 541-552.	0.8	10
83	No Association Between Antidepressant Efficacy and rs28365143 in Corticotropin-Releasing Hormone Binding Protein in a Large Meta-Analysis. <i>American Journal of Psychiatry</i> , 2018, 175, 575-576.	4.0	1
84	Pharmacogenetics in Psychiatry. <i>Advances in Pharmacology</i> , 2018, 83, 297-331.	1.2	31
85	22q11.2 rearrangements: clinical and research implications of population-based risk of neuropsychiatric and developmental disorders. <i>Lancet Psychiatry</i> , 2018, 5, 531-532.	3.7	1
86	International Union of Basic and Clinical Pharmacology CIV: The Neurobiology of Treatment-resistant Depression: From Antidepressant Classifications to Novel Pharmacological Targets. <i>Pharmacological Reviews</i> , 2018, 70, 475-504.	7.1	42
87	Refining Prediction in Treatment-Resistant Depression. <i>Journal of Clinical Psychiatry</i> , 2018, 79, 16m11385.	1.1	76
88	Pharmacogenetics of antidepressant response: A polygenic approach. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 75, 128-134.	2.5	71
89	Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 723-735.	1.8	21
90	Electrocardiogram Alterations Associated With Psychotropic Drug Use and CACNA1C Gene Variants in Three Independent Samples. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2017, 120, 482-490.	1.2	10

#	ARTICLE	IF	CITATIONS
91	Is a polygenic predictor of antidepressant response a possibility?. <i>Pharmacogenomics</i> , 2017, 18, 749-752.	0.6	4
92	New Insights Into The Pharmacogenomics Of Antidepressant Response From The Gendep And Star*D Studies: Results Of Rare Variant Analysis And High-Density Imputation. <i>European Neuropsychopharmacology</i> , 2017, 27, S443-S444.	0.3	0
93	Cariprazine specificity profile in the treatment of acute schizophrenia. <i>International Clinical Psychopharmacology</i> , 2017, 32, 309-318.	0.9	27
94	Role of 108 schizophrenia-associated loci in modulating psychopathological dimensions in schizophrenia and bipolar disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2017, 174, 757-764.	1.1	38
95	Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 5-28.	1.3	75
96	Meta-analysis of CYP2C19 association with efficacy and side effects of citalopram and escitalopram. <i>European Neuropsychopharmacology</i> , 2017, 27, S582-S583.	0.3	0
97	Role of 108 schizophrenia-associated loci in modulating psychopathological dimensions in schizophrenia and bipolar disorder. <i>European Neuropsychopharmacology</i> , 2017, 27, S583.	0.3	0
98	Potential genes behind the difference between bipolar I and bipolar II disorder. <i>European Neuropsychopharmacology</i> , 2017, 27, S836-S837.	0.3	0
99	Association between CACNA1C gene rs1034936 polymorphism and alcoholism in bipolar disorder. <i>European Neuropsychopharmacology</i> , 2017, 27, S1057-S1058.	0.3	0
100	Genetic and Environmental Contribution to Major Depressive Disorder and Self-declared Depression. <i>EBioMedicine</i> , 2016, 14, 7-8.	2.7	10
101	ECG alterations associated with psychotropic drug use in clinical settings: clinical and genetic predictors. <i>European Neuropsychopharmacology</i> , 2016, 26, S240-S241.	0.3	0
102	HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyv125.	1.0	26
103	Cognitive function and risperidone long-acting injection vs. paliperidone palmitate in schizophrenia: a 6-month, open-label, randomized, pilot trial. <i>BMC Psychiatry</i> , 2016, 16, 172.	1.1	16
104	Progress and prospects in pharmacogenetics of antidepressant drugs. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1157-1168.	1.5	30
105	Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway. <i>BMC Psychiatry</i> , 2016, 16, 106.	1.1	24
106	Remifentanyl in electroconvulsive therapy: a systematic review and meta-analysis of randomized controlled trials. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2016, 266, 703-717.	1.8	24
107	Pharmacogenetics of the Efficacy and Side Effects of Antidepressant Drugs. , 2016, , 39-54.		1
108	The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial. <i>Neuropsychobiology</i> , 2016, 73, 35-42.	0.9	21

#	ARTICLE	IF	CITATIONS
109	Glutamatergic and HPA-axis pathway genes in bipolar disorder comorbid with alcohol- and substance use disorders. <i>Metabolic Brain Disease</i> , 2016, 31, 183-189.	1.4	6
110	Genetics of long-term treatment outcome in bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 65, 17-24.	2.5	39
111	Age of Onset in Schizophrenia Spectrum Disorders: Complex Interactions between Genetic and Environmental Factors. <i>Psychiatry Investigation</i> , 2016, 13, 247.	0.7	15
112	The Role of Pharmacogenetics in Pharmacovigilance of Psychotropic Drugs. , 2016, , 121-146.		0
113	Serotonin 7 Receptor Variants Are Not Associated with Response to Second-Generation Antipsychotics in Japanese Schizophrenia Patients. <i>Neuropsychobiology</i> , 2015, 72, 118-125.	0.9	8
114	Genetics of second-generation antipsychotic and mood stabilizer-induced weight gain in bipolar disorder. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 354-362.	0.7	15
115	HTR1A Gene Polymorphisms and 5-HT1A Receptor Partial Agonist Antipsychotics Efficacy in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 220-227.	0.7	22
116	Pharmacogenetics of Major Depressive Disorder: Top Genes and Pathways Toward Clinical Applications. <i>Current Psychiatry Reports</i> , 2015, 17, 50.	2.1	69
117	Schizophrenia-Like Symptoms in Narcolepsy Type 1: Shared and Distinctive Clinical Characteristics. <i>Neuropsychobiology</i> , 2015, 71, 218-224.	0.9	29
118	Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients. <i>Journal of Neural Transmission</i> , 2015, 122, 43-58.	1.4	14
119	A model to investigate SNPsâ€™ interaction in GWAS studies. <i>Journal of Neural Transmission</i> , 2015, 122, 145-153.	1.4	3
120	CHL1,ITGB3andSLC6A4gene expression and antidepressant drug response: results from the Munich Antidepressant Response Signature (MARS) study. <i>Pharmacogenomics</i> , 2015, 16, 689-701.	0.6	22
121	Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 579-588.	1.8	5
122	Neuronal cell adhesion genes and antidepressant response in three independent samples. <i>Pharmacogenomics Journal</i> , 2015, 15, 538-548.	0.9	34
123	Predictors of switch from depression to mania in bipolar disorder. <i>Journal of Psychiatric Research</i> , 2015, 66-67, 45-53.	1.5	26
124	P.1.a.002 Genetics of long-term treatment outcome in bipolar disorder. <i>European Neuropsychopharmacology</i> , 2015, 25, S159-S160.	0.3	0
125	Pharmacogenetics of Antidepressant Drugs. , 2014, , 543-562.		0
126	Genes involved in neuroplasticity and stressful life events act on the short-term response to antidepressant treatment: a complex interplay between genetics and environment. <i>Human Psychopharmacology</i> , 2014, 29, 388-391.	0.7	11

#	ARTICLE	IF	CITATIONS
127	Serotonin Transporter Gene: A New Polymorphism May Affect Response to Antidepressant Treatments in Major Depressive Disorder. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 567-577.	1.6	19
128	DISC1-TSNAX and DAOA genes in major depression and citalopram efficacy. <i>Journal of Affective Disorders</i> , 2014, 168, 91-97.	2.0	15
129	Understanding the pharmacogenetics of selective serotonin reuptake inhibitors. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1093-1118.	1.5	14
130	PPP3CC gene: a putative modulator of antidepressant response through the B-cell receptor signaling pathway. <i>Pharmacogenomics Journal</i> , 2014, 14, 463-472.	0.9	41
131	P.1.014 PPP3CC: a new candidate gene in antidepressant response. <i>European Neuropsychopharmacology</i> , 2014, 24, S14-S15.	0.3	0
132	From Pharmacogenetics to Pharmacogenomics: The Way toward the Personalization of Antidepressant Treatment. <i>Canadian Journal of Psychiatry</i> , 2014, 59, 62-75.	0.9	46
133	Screening genetic variability at the CNR1 gene in both major depression etiology and clinical response to citalopram treatment. <i>Psychopharmacology</i> , 2013, 227, 509-519.	1.5	51
134	Pharmacogenetics of antidepressant drugs: An update after almost 20 years of research. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2013, 162, 487-520.	1.1	77
135	S.25.03 Pharmacogenetics of efficacy and treatment side effects in bipolar disorder. <i>European Neuropsychopharmacology</i> , 2013, 23, S148.	0.3	0
136	Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR α D. <i>European Neuropsychopharmacology</i> , 2013, 23, 612-621.	0.3	26
137	Clinical features and drug induced side effects in early versus late antidepressant responders. <i>Journal of Psychiatric Research</i> , 2013, 47, 1309-1318.	1.5	26
138	P.1.a.016 CHL1 gene: a new promising antidepressant response marker in major depression. <i>European Neuropsychopharmacology</i> , 2013, 23, S168-S169.	0.3	0
139	P.2.f.014 PPP3CC gene in antidepressant response: results from three independent samples. <i>European Neuropsychopharmacology</i> , 2013, 23, S403.	0.3	0
140	Shared genetics among major psychiatric disorders. <i>Lancet, The</i> , 2013, 381, 1339-1341.	6.3	70
141	Pharmacogenetics in major depression: A comprehensive meta-analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 45, 183-194.	2.5	174
142	Side effects associated with psychotropic medications in patients with bipolar disorder: evidence from two independent samples. <i>Journal of Psychopharmacology</i> , 2013, 27, 616-628.	2.0	19
143	TPH1, MAOA, Serotonin Receptor 2A and 2C Genes in Citalopram Response: Possible Effect in Melancholic and Psychotic Depression. <i>Neuropsychobiology</i> , 2013, 67, 41-47.	0.9	30
144	Genetics of Serotonin Receptors and Depression: State of the Art. <i>Current Drug Targets</i> , 2013, 14, 531-548.	1.0	26

#	ARTICLE	IF	CITATIONS
145	No Effect of Serotonergic Gene Variants on Response to Interpersonal Counseling and Antidepressants in Major Depression. <i>Psychiatry Investigation</i> , 2013, 10, 180.	0.7	20
146	Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. <i>European Neuropsychopharmacology</i> , 2012, 22, 239-258.	0.3	283
147	Mechanisms of antidepressant action: An integrated dopaminergic perspective. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1532-1543.	2.5	38
148	P.2.c.026 Rapid versus slow titration of paroxetine antidepressant treatment in elderly population: an observational study. <i>European Neuropsychopharmacology</i> , 2011, 21, S397-S398.	0.3	0
149	Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1101-1115.	1.5	64
150	Pharmacogenetics of Antidepressants. <i>Frontiers in Pharmacology</i> , 2011, 2, 6.	1.6	72
151	Pharmacogenetics of antidepressant response. <i>Journal of Psychiatry and Neuroscience</i> , 2011, 36, 87-113.	1.4	144
152	Abnormal brain hemodynamic responses during passive orthostatic challenge in panic disorder. <i>American Journal of Psychiatry</i> , 1997, 154, 378-383.	4.0	26